STOCK TITAN
  1. Home
  2. Sec-filings
  3. RCUS
  4. [Form 4] Arcus Biosciences, Inc. Insider Trading Activity

Arcus Biosciences (RCUS) grants CFO 24K RSUs and 96K options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Arcus Biosciences granted Chief Financial Officer Robert C. Goeltz II new equity awards. On 01/23/2026, he received 24,000 shares of common stock in the form of restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, as long as he continues serving the company.

He was also granted a stock option to buy 96,000 shares of common stock at an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to his continued service. Following the RSU grant, he beneficially owned 91,924 shares of common stock directly, which includes unvested RSUs.

Positive

  • None.

Negative

  • None.
Insider Goeltz II Robert C.
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 96,000 $0.00 --
Grant/Award Common Stock 24,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 96,000 shares (Direct); Common Stock — 91,924 shares (Direct)
Footnotes (1)
  1. Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. Includes the unvested portion of the Reporting Person's RSU grants. The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Goeltz II Robert C.
(Last) (First) (Middle)
C/O ARCUS BIOSCIENCES, INC.
3928 POINT EDEN WAY
(Street)
HAYWARD CA 94545
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/23/2026 A 24,000(1) A $0 91,924(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $22.13 01/23/2026 A 96,000 (3) 01/22/2036 Common Stock 96,000 $0 96,000 D
Explanation of Responses:
1. Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
2. Includes the unvested portion of the Reporting Person's RSU grants.
3. The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
Remarks:
/s/ Carolyn Tang, Attorney-in-Fact 01/26/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Arcus Biosciences (RCUS) report for its CFO?

Arcus Biosciences reported that Chief Financial Officer Robert C. Goeltz II received equity awards on 01/23/2026, including a grant of restricted stock units and a stock option to purchase common stock.

How many restricted stock units did the Arcus (RCUS) CFO receive?

The CFO received 24,000 shares of common stock in the form of restricted stock units, granted at a price of $0.

What is the vesting schedule for the CFOs RSUs at Arcus Biosciences?

The 24,000 RSUs vest in four equal annual installments starting on December 15, 2026, contingent on the CFOs continued service to the company.

What stock options were granted to the Arcus Biosciences (RCUS) CFO?

He was granted a stock option for 96,000 shares of common stock with an exercise price of $22.13 per share, recorded as a grant at $0 on the transaction date.

How do the new stock options for the Arcus (RCUS) CFO vest?

The option for 96,000 shares becomes exercisable in 48 equal monthly installments after January 1, 2026, as long as the CFO continues his service with the company.

How many Arcus Biosciences shares does the CFO beneficially own after these grants?

After the reported transaction, the CFO beneficially owned 91,924 shares of Arcus Biosciences common stock directly, including the unvested portion of his RSU grants.